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Abstract 
Aims: Real-world evidence of the safety of insulin degludec compared to insulin glargine U100 is sparse. 
This study sought to investigate the risk of major cardiovascular events, severe hypoglycemia and all-
cause mortality after initiation of degludec or glargine U100 in the population of Denmark.   
Materials and Methods: All Danish people with diabetes initiating treatment on degludec (n=5,159) or 
glargine (n=4,041) in 2016-17 were included in the study. The effect of insulin treatment on the 
endpoints of major cardiovascular events, severe hypoglycemia and all-cause mortality was analysed 
with Cox proportional hazard models. The models were adjusted for age, sex, diabetes duration, 
diabetes type, highest completed education and annual income. The model of severe hypoglycemia 
was also adjusted for severe hypoglycemia prior to baseline. The model of mortality was also adjusted 
for history of alcohol abuse, use of antidepressants, use of opioids and use of anxiolytics. Lastly, the 
models of major cardiovascular events and mortality were also adjusted for Charlson comorbidity index. 
Results: Use of degludec resulted in an almost 2-fold decrease in risk of death (HR: 0.54, 95% CI: 0.44-
0.65) compared to use of glargine. No statistically significant risk changes were found for major 
cardiovascular events (HR: 0.86, 95% CI: 0.62-1.19) and severe hypoglycemia (HR: 1.13, 95% CI: 0.66-
1.93). The proportion of cause of death due to malignant neoplasm of pancreas was almost doubled 
for glargine compared to degludec. 
Conclusions: These results indicate that insulin degludec has a safer profile with respect to all-cause 
mortality as compared to insulin glargine U100. 
 
Introduction 
Insulin degludec is an ultra-long acting insulin producing a flat glucose-lowering profile to improve the 
imitation of the pancreatic basal insulin secretion[1]. An indication for clinicians to recommend patients 
to switch from other long acting insulins to insulin degludec is among others issues with 
hypoglycemia[2]. In the DEVOTE study[3], Pratley et al. investigated 7,637 people with type 2 diabetes 
and found a comparable risk of major cardiovascular events (MACE) and all-cause mortality for users 
of insulin degludec compared to glargine U100 with a slight statistically insignificant favoring towards 
degludec. However, the risk of severe hypoglycemia was statistically significantly lower for users of 
insulin degludec. In a meta-analysis of 4,330 people with both type 1 diabetes and type 2 diabetes, 
Ratner et al.[4] found that users of degludec experienced significant lower rates of particularly nocturnal 
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hypoglycemic events as compared to users of glargine. In another meta-analysis by Zhang et al.[5] 
investigating 16,791 people with type 1 diabetes and type 2 diabetes, similar outcomes were observed: 
Risk reduction in confirmed and nocturnal hypoglycemia for users of degludec compared to glargine 
U100, but no statistically significant difference in cardiovascular events and all-cause mortality.  
Evidence of the safety of insulin degludec vs glargine U100 is rich with respect to controlled settings 
and sometimes unnatural population selections in randomized controlled trials (RCTs). For example, 
an exclusion criterion of previous malignant neoplasm[6] is unnatural in the sense that strong evidence 
for a positive association between diabetes and cancer exists[7], thereby making cancer a natural part 
of the diabetes population. Another example is the exclusion criterion of hypoglycemia unawareness in 
a basal-bolus study of people with type 1 diabetes[8], which is unnatural because around one fifth of 
the type 1 diabetes population suffers from impaired awareness[9]. On the other hand, real-world 
evidence of the safety is sparse. In a small real-world study of degludec vs glargine U100 in a previous 
insulin-naïve population in India, Ghosal et al.[10] found less patient-recorded hypoglycemic episodes 
for degludec compared to glargine U100 users. In a prospective cohort study of 80 people with type 1 
diabetes and type 2 diabetes switched to degludec from another basal insulin, Kobuke et al.[11] found 
that degludec can maintain glucose control at a lower insulin dose and frequency of hypoglycemia in 
type 1 diabetes, and improve glycemic control at an equal insulin dose in type 2 diabetes. 
These small real-world studies add to the evidence shown in the larger RCTs that degludec reduces 
the risk of hypoglycemia as compared to glargine U100. However, investigation of major cardiovascular 
events and all-cause mortality in real-world studies remain sparse. 
This study sought to investigate the hypothesis that risk of major cardiovascular events, severe 
hypoglycemia and all-cause mortality is lower after initiation of insulin degludec compared to insulin 
glargine U100 in the population of Denmark.   
 
 
Materials and Methods 
 
Study design 
This study was carried out using a cohort of all adult people in Denmark initiating basal insulin treatment 
on either insulin degludec (Novo Nordisk A/S, Bagsvaerd, Denmark) or insulin glargine (Sanofi, Paris, 
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France) from 2016 to 2017. A general reimbursement of insulin degludec was approved in Denmark 
with effect from January 4th, 2016[12], and a significant use of degludec thus started in 2016. Data were 
extracted from the Danish National Patient Registry (DNPR). Date of initiation of insulin degludec or 
insulin glargine defined baseline for each person. The follow-up period was terminated at the dispense 
of another insulin product after baseline. People with dispensed bolus insulin in the year before basal 
insulin initiation were excluded. Dispenses of degludec and glargine were extracted from The National 
Pharmacological Database using the Anatomical Therapeutical Chemical (ATC) classification code of 
A10AE (Insulins and analogues for injection, long-acting) and the product names of Tresiba (insulin 
degludec) and Lantus (insulin glargine). Bolus insulins were found in the same database from the ATC 
code A10AB (Insulins and analogues for injection, fast-acting). From all Danish adult citizens in 2016-
17, 313,690 people were diagnosed with diabetes. 5,159 people initiated treatment on insulin degludec, 
whereas 4,041 initiated treatment on insulin glargine U100.  
 
Endpoints 
Three endpoints were defined in this study: 1) Major cardiovascular event (MACE), 2) severe 
hypoglycemia and 3) death. The endpoints were found via the International Classification of Diseases 
10 (ICD-10) system. MACE is a composite endpoint consisting of nonfatal acute myocardial infarctions, 
nonfatal ischemic strokes and cardiovascular deaths. Nonfatal acute myocardial infarctions were found 
from the ICD-10 code DI21 (Acute myocardial infarction) and nonfatal ischemic strokes from DI61 
(Nontraumatic intracerebral hemorrhage). Cardiovascular deaths were extracted from the Danish 
Register of Causes of Death via the ICD-10 codes of DI00-DI99 (Diseases of the circulatory system). 
Hypoglycemic episodes were identified via the ICD-10 codes DE160 (drug-induced hypoglycemia 
without coma), DE161 (other hypoglycemia) and DE162 (Hypoglycemia, unspecified). They were 
characterized as severe because they were related to hospital admissions. The last endpoint of death 
was defined as all-cause deaths extracted from the Danish Register of Causes of Death. 
 
Source of data 
Diagnoses used for endpoints and covariates came from The Danish National Patient Register 
(DNPR)[13]. DNPR was established in 1977 and initially covered information on inpatient in somatic 
wards. Since then it has been expanded and now includes information on all patients in Danish 
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hospitals[13]. The validity of registrations is high[14,15], especially, registrations related to 
MACE[16,17]. 
Information about drug use came from The National Pharmacological Database by the Danish 
Medicines Agency, which is a nationwide register of medicines sold after 1996. Information about 
mortality came from the Danish Register of Causes of Death, which is a register of all deaths since 
1875 and is managed by the National Board of Health[18]. 
 
Statistical analysis 
Descriptive statistics are presented with mean and standard deviation (SD) or percentage of people. 
Unpaired T-tests, Chi-square tests and Mann-Whitney U tests will be used to present statistical 
differences in person characteristics. Age was calculated as years from date of birth to baseline. 
Diabetes duration was calculated as years from date of diagnosis to baseline. Insulin dose was 
calculated by dividing each dose (in international units – IU) with the duration to the next dispense to 
get daily dose per dispense. Median of all dose dispenses per person was then calculated. Finally, 
grand median per treatment was calculated and is presented with interquartile ranges (IQR).  as the 
median dose for each patientEnrolled people were stratified into type 1 diabetes or type 2 diabetes 
based on codes from the Anatomical Therapeutical Chemical (ATC) classification system. They were 
classified as type 2 diabetes (n=8,618) if they had at least one A10B (blood glucose lowering drugs, 
excl. insulins) ATC code; otherwise they were classified as type 1 diabetes (n=582). Kaplan-Meier 
curves were applied to illustrate unadjusted time to each of the three endpoints, whereas Cox 
proportional hazards models were applied to analyse adjusted and unadjusted effect of treatment on 
each of the three endpoints. People enrolled were considered censored at the first date of emigration 
or end of follow-up (31st December 2017). The proportional hazards models were adjusted for age, 
sex, diabetes duration and diabetes type. Furthermore, they were adjusted for socioeconomic factors 
of highest completed education and yearly income prior to baseline. Yearly gross income per person 
was stratified in Low (<200,000 DKK  30,000 USD), Normal (200,000-500,000 DKK  30,000-75,000 
USD) or High (>500,000 DKK  75,000 USD). Highest completed education was stratified in <High-
school graduate (or equal) or >High-school graduate. The model of severe hypoglycemia was adjusted 
for occurrence of at least one severe hypoglycemia prior to baseline. The model of mortality was 
adjusted for history of alcohol abuse (ICD-10: DF10, DZ721), use of antidepressants (ATC: N06AA), 
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use of opioids (ATC: N02A) and use of anxiolytics (ATC: N05B) prior to baseline. The models of MACE 
and mortality were adjusted for Charlson comorbidity index[19]. Comorbidities related to MACE were 
excluded from the index, and the comorbidities searched for prior to baseline and associated scores 
were Cardiac insufficiency (1, ICD-10: DI50, DI110, DI130, DI132), Cardiovascular disease (1, ICD-10: 
DI70, DI71, DI72, DI73, DI74, DI77), Cerebrovascular disease (1, ICD-10: DI60, DI61-9, DG45, DG46), 
Dementia (1, ICD-10: DF00-DF03, DF051, DG30), Chronic pulmonary disease (1, ICD-10: DJ40-DJ47, 
DJ60-DJ67, DJ684, DJ701, DJ703, DJ841, DJ920, DJ961, DJ982, DJ983), Connective tissue disease 
(1, ICD-10: DM05, DM06, DM08, DM09, DM30, DM31, DM32, DM33, DM34, DM35, DM36, DD86), 
Peptic Ulcer (1, ICD-10: DK221, DK25-DK28), Mild liver disease (1, ICD-10: DB18, DK700-DK703, 
DK709, DK71, DK73, DK74, DK760), Diabetes mellitus (1, ICD-10: DE100, DE101, DE109, DE110, 
DE111, DE119), Hemiplegia (1, ICD-10: DG81, DG82), Nephrological disease (2, ICD-10: DI12, DI13, 
DN00-DN05, DN07, DN11, DN14, DN17-DN19, DQ61), Late-diabetic complications (2, ICD-10: DE102-
DE108, DE112-DE118), Solid cancers (2, ICD-10: DC00-DC75), Leukemia (2, ICD-10: DC91-DC95), 
Lymphoma (2, ICD-10: DC81-DC85, DC88, DC90, C96), Moderate to severe liver disease (3, ICD-10: 
DB150, DB160, DB162, DB190, DK704, DK72, DK766, DI85), Metastatic cancer (6, ICD-10: DC76-
DC80), AIDS (6, ICD-10: DB21-DB24). Finally, the five most frequent causes of death were found and 
the distribution across treatments are summarized.   
 
Results 
 
Table 1 shows the baseline characteristics of people enrolled in this study. Less users of glargine than 
degludec were found. Age, sex and socioeconomic factors were fairly equally distributed between the 
two treatments. Degludec users had a longer diabetes duration. More type 1 diabetes people were 
users of glargine and more type 2 diabetes people were users of degludec. Degludec users had in 
general a higher insulin dose. The Charlson comorbidity index was slightly higher for glargine users. 
Furthermore, a larger proportion of glargine users had a history of alcohol abuse. On the other hand, a 
larger proportion of degludec users were on opioids and anxiolytics before baseline. Time-to-event 
curves derived from Kaplan-Meier analyses are presented in Figure 1. A separation of the treatments 
from time zero favoring degludec can be observed for time to MACE and time to death. Time to severe 
hypoglycemia shows inconclusive results but an indication of a favoring of glargine half a year after 
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initiation of treatment may be observed. However, only about half of the population is present in the last 
half year. In Table 2, unadjusted and adjusted hazard rate ratios (HR) and 95% confidence intervals 
(CI) are shown for degludec/glargine. Unadjusted HRs and CIs are similar to the adjusted versions, and 
the indications are similar to those of the time-to-event curves. Risk of MACE is reduced for degludec 
compared to glargine, but the results are not statistically significant. Risk of severe hypoglycemia is 
increased for degludec compared to glargine, but the results are not statistically significant. Risk of all-
cause mortality is statistically significantly decreased for degludec compared to glargine. Being female 
reduced the risk of MACE (HR: 0.64, CI 95%: 0.45-0.90), severe hypoglycemia (HR: 0.84, CI 95%: 
0.49-1.44) and all-cause mortality (HR: 0.83, CI 95%: 0.69-1.01), but only the former was statistically 
significant. In Table 3 the five most frequent causes of death are summarized across treatments. The 
excessive deaths among people using glargine is from the top five death causes mainly driven by 
pancreatic malignancy.  
 
 
Discussion 
In this study, we investigated risk of major cardiovascular events (MACE), severe hypoglycemia and 
all-cause mortality after initiation of insulin degludec or insulin glargine U100 in the population of 
Denmark in 2016-17. Risk of MACE and severe hypoglycemia was decreased and increased, 
respectively, for degludec compared to glargine, but the results were not statistically significant. 
Furthermore, a statistically significant approximately 2-fold risk reduction of all-cause mortality could be 
observed for degludec compared to glargine. 
In several randomized controlled trials (RCTs), a risk reduction with respect to hypoglycemia has been 
observed for degludec compared to glargine[3–5]. In this study, we were unable to demonstrate this 
link. In the first half year of initiation of degludec or glargine, a small favoring of degludec was observed, 
but in the next half year, glargine is favored leading to a statistically insignificant 1-year risk increase for 
degludec compared to glargine. It should be noted that the number of episodes is low (59). Furthermore, 
the episodes investigated in this study are all related to hospital admission. In other studies, e.g. the 
DEVOTE study[3], the American Diabetes Association’s definition of an episode requiring assistance of 
another person to actively administer carbohydrate or glucagon, or to take other corrective actions[20] 
is typically used. This different definition and the number of episodes might explain the results and the 
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statistically insignificance with respect to hypoglycemia. A protective effect of degludec compared to 
glargine with respect to MACE was observed in this study, but the effect was not statistically significant. 
These results are comparable with findings from the DEVOTE study by Pratley et al.[3] and a meta-
analysis by Zhang et al.[5]. In the DEVOTE study, a MACE risk reduction of 12% for people with type 2 
diabetes aged 65-74 was shown, which is comparable with the 14% risk reduction shown in this study. 
Both results were not statistically significant though.  
On the other hand, a statistically significant protective effect of degludec compared to glargine with 
respect to death was observed. The risk of death was decreased by 46% for people on degludec 
compared to glargine. In the DEVOTE study[3], people above 75 years or between 50 and 65 years 
using degludec had a reduced risk of death compared to glargine but both results were not statistically 
significant. In the meta-analysis by Zhang et al.[5], a 10% reduced risk of total mortality was observed 
for people on degludec compared to glargine, but this result was not statistically significant either. 
Compared to DEVOTE, the population of this study differs due to inclusion of people with type 1 
diabetes. However, people with type 1 diabetes were also included in the meta-analysis by Zhang et al. 
In the DEVOTE study, several eligibility criteria[6] make comparison with the real-world population of 
this study difficult. First of all, an inclusion criterion was age above or equal to 50 years with predefined 
previous cardiovascular disease(s) or renal disease or age above or equal to 60 years with predefined 
cardiovascular risk factors. Secondly, an exclusion criterion was current or past (within the last 5 years) 
malignant neoplasm (except basal cell and squamous cell skin carcinoma). In the top five frequent 
causes of death in our study, malignant pancreatic neoplasm was more frequent among users of 
glargine compared to degludec, and if malignant disposed people were excluded in the DEVOTE study, 
this could be one of the reasons behind the discrepancy in risk of death among the studies. It should 
be noted that pancreas cancer is probably not induced within the follow-up period of one year, but the 
insulin treatment could induce progression of existing malignant dysplasia. 
In the past, an association between insulin analogues and risk of cancers has been suspected[21]. 
Especially, insulin glargine, as the first long-acting insulin analogue produced by recombinant DNA 
technology, has been in focus[7]. In a study by Hemkens et al.[22], a cancer risk increase of 9-31% was 
found for glargine compared to human insulin. In other studies increase in risk of cancer was also linked 
to glargine[23–25]. However, in a follow-up study, one of the previous findings were proven to be 
random[26]. In an expert opinion by Rendell et al.[7], this example with a wrong conclusion led to 
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criticism of retrospective epidemiological studies with a conclusion pointing towards that controlled 
clinical trials are the only means to definitely prove hypotheses. We agree to this point, but as previously 
discussed, the issue with randomized controlled trials is that the included population is seldom 
completely generalizable, and at least a part of the mortality difference between this study and DEVOTE 
can be explained by this. 
It can be observed that the diabetes duration is longer in the degludec group compared to glargine. One 
explanation could be a better mortality benefit as discussed above for degludec as compared to 
glargine. Another explanation could be that an indication for switching to degludec is issues with 
hypoglycemia, and risk of severe hypoglycemia increases with diabetes duration[27], which could 
explain the higher diabetes duration among degludec users. Another observation is the higher insulin 
dose among degludec users. In treat-to-target trials, a higher dose of degludec has been observed[6] 
but not with the same magnitude. The higher dose might also be related to that people initiating 
treatment on insulin degludec are more insulin resistant with history of severe hypoglycemia, for 
example, on insulin glargine where a relatively low insulin dose has been necessary. When they are 
then switched to insulin degludec the dose is being increased.   
A limitation of our study is the lack of information about body mass index and glycemic control. Body 
mass index could be a confounder, and it would be valuable to know the glycemic control, for example 
in terms of HbA1c in the two treatment groups. If the glycemic control was known and approximately 
equal among treatments, it would have enabled adjustment of insulin dose. The higher degludec dose 
might affect degludec’s better outcome with respect to severe hypoglycemia compared to glargine as 
seen in other studies, but without information about glycemic control in this study, it would be misleading 
to adjust for insulin dose. Another limitation is the definition of severe hypoglycemia. Since only 19% of 
severe hypoglycemic episodes lead to hospital admissions[28], the actual incidences of severe 
hypoglycemia are much higher than in this study, which may have led to the inconclusive result. A third 
limitation is definition of basal insulin use. Only dates of insulin dispense were available and these are 
not necessarily the dates of basal insulin initiations. An improvement to the study design could have 
been to match type 2 diabetes people between the two groups based on their oral antidiabetic 
medication. However, in this study it was not possible due to the low number of events under 
investigation. Finally, a limitation is the origin of causes of death. Death causes are registered in the 
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Danish Civil Registration System, typically, by general practitioners in everyday situations where 
register research is not on their mind. This means that more general causes of death might be used.  
In conclusion, this study indicates a decreased risk of major cardiovascular events and an increased 
risk of severe hypoglycemia for people on insulin degludec compared to insulin glargine U100. 
However, both results were not statistically significant. On the other hand, a statistically significant 
approximately 2-fold reduced risk of death was found for degludec compared to glargine U100, which 
suggest that degludec has a safer profile than glargine with respect to all-cause mortality. These results 
add to the evidence that degludec has a safer profile, which should be considered when choosing 
treatment in clinical practice. 
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Table 1: Characteristics at baseline for people enrolled in this study. 
 Degludec Glargine P 
Number of people 5,159 4,041  
Age (yrs), mean (SD) 66 (13) 65 (15) 0.1490 
Sex    
Female (%) 39.6 40.0 0.6558 
Male (%) 60.4 60.0 0.6558 
Diabetes duration (yrs), mean (SD) 13 (7) 10 (7) <.0001 
Diabetes type 
Type 1 (%) 
Type 2 (%) 
 
4.8 
95.2 
 
8.2 
91.8 
 
<.0001 
<.0001 
Insulin dose (IU/day), median (IQR) 38 (24-58) 28 (19-43) <0.001 
MACE during follow-up, n (%) 81 (1.6) 76 (1.9) 0.2535 
Severe hypoglycemia during follow-up, n (%) 35 (0.7) 24 (0.6) 0.6143 
Severe hypoglycemia before baseline, n (%) 251 (4.9) 152 (3.8) 0.0102 
Died during follow-up, n (%) 215 (4.2) 369 (9.1) <.0001 
Highest completed education (%)    
<High-school graduate 52.1 52.3 0.7939 
>High-school graduate 47.0 46.5 0.6360 
Income (%)    
Low 50.0 52.5 0.0148 
Normal 34.7 31.2 0.0004 
High 14.8 14.9 0.8187 
Charlson comorbidity index, mean (SD) 2.9 (2.4) 3.2 (2.6) <.0001 
History of alcohol abuse (%) 6.7 8.6 0.0007 
Use of antidepressants (%) 39.3 40.4 0.2737 
Use of opioids (%) 14.6 13.2 0.0580 
Use of anxiolytics (%) 65.3 63.5 0.0696 
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Figure 1: Time to event in a 1-year follow-up after initiation of degludec and glargine. Graph A is time 
to major cardiovascular event, graph B is time to severe hypoglycemia and graph C is time to death. 
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Table 2: Unadjusted and adjusted hazard rate ratios (HR) for degludec/glargine 
from the Cox proportional hazard models are shown in the table together with 95% 
confidence intervals (CI) and p values (p). 
Models HR (95% CI) p 
Unadjusted   
Time to major cardiovascular events 0.82 (0.60-1.13) 0.2267 
Time to severe hypoglycemia 1.14 (0.68-1.91) 0.6322 
Time to death *0.44 (0.37-0.53) <.0001 
Adjusted   
Time to major cardiovascular eventsa 0.86 (0.62-1.19) 0.3687 
Time to severe hypoglycemiab 1.13 (0.66-1.93) 0.6661 
Time to deathc *0.54 (0.44-0.65) <.0001 
a Adjusted for age, sex, diabetes duration, diabetes type, education, income, 
Charlson comorbidity index and date of treatment initiation 
b Adjusted for age, sex, diabetes duration, diabetes type, education, income, severe 
hypoglycemia before baseline and date of treatment initiation 
c Adjusted for age, sex, diabetes duration, diabetes type, education, income, 
Charlson comorbidity index, history of alcohol abuse, use of antidepressants, use 
opioids, use of anxiolytics and date of treatment initiation 
* Statistically significant result (p<0.05) 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 3: The five most frequent causes of death in the follow-up period of the cohort. Number of people 
and percentage within the group is shown. 
Five most frequent causes of death, n (%) Degludec Glargine 
Malignant neoplasm of pancreas, unspecified (DC259) 7 (3.3) 22 (6.0) 
Malignant neoplasm of unspecified part of bronchus or lung (DC349) 10 (4.7) 17 (4.6) 
Malignant neoplasm of overlapping sites of pancreas (DC258) 8 (3.7) 15 (4.1) 
Ill-defined and unknown cause of mortality (DR990) 7 (3.3) 12 (3.3) 
Heart failure, unspecified (DI509) 7 (3.3) 7 (1.9) 
 
